Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

837 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience.
Valenti M, D'Arino A, Melis E, Carugno A, Sena P, Frascione P, Cota C, Piscazzi F, Mercuri SR, Russo V, Damiano G, Bulotta A, Marzano AV, Mattioli MA, Borroni RG, Narcisi A, Costanzo A, Ardigò M, Paolino G. Valenti M, et al. Among authors: costanzo a. J Clin Med. 2024 Oct 28;13(21):6445. doi: 10.3390/jcm13216445. J Clin Med. 2024. PMID: 39518584 Free PMC article.
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Warren RB, Pavlovsky L, Costanzo A, Bukhalo M, Korman NJ, Huang YH, Kokolakis G, Pinter A, Ibrahim N, Zheng Y, Drogaris L, Stakias V, Soliman AM, Rubant S, Thaçi D. Warren RB, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2024 Nov 8. doi: 10.1007/s13555-024-01292-z. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 39516454
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study.
Ibba L, Di Giulio S, Gargiulo L, Facheris P, Perugini C, Costanzo A, Narcisi A, Valenti M. Ibba L, et al. Among authors: costanzo a. J Dermatolog Treat. 2024 Dec;35(1):2425029. doi: 10.1080/09546634.2024.2425029. Epub 2024 Nov 7. J Dermatolog Treat. 2024. PMID: 39510528 Free article.
More than one effect in every affect.
Costanzo A, Musetti A, Rossi R, Schimmenti A. Costanzo A, et al. Phys Life Rev. 2024 Oct 18;51:273-280. doi: 10.1016/j.plrev.2024.10.008. Online ahead of print. Phys Life Rev. 2024. PMID: 39490140 No abstract available.
Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome.
Giordano S, Ielapi J, Salerno N, Cersosimo A, Lucchino A, Laschera A, Canino G, Di Costanzo A, De Rosa S, Torella D, Sorrentino S. Giordano S, et al. Among authors: di costanzo a. Rev Cardiovasc Med. 2024 Oct 22;25(10):374. doi: 10.31083/j.rcm2510374. eCollection 2024 Oct. Rev Cardiovasc Med. 2024. PMID: 39484117 Free PMC article. Review.
Efficacy and Safety of Upadacitinib Versus Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Four Body Regions: Analysis From the Heads-Up Study.
Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, Ladizinski B, Hu X, Liu Y, Calimlim B, Nduaka C, Vigna N, Armstrong A. Thyssen JP, et al. Among authors: costanzo a. Dermatology. 2024 Oct 30:1-17. doi: 10.1159/000542275. Online ahead of print. Dermatology. 2024. PMID: 39476813 Free article.
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.
Campione E, Artosi F, Shumak RG, Giunta A, Argenziano G, Assorgi C, Balato A, Bernardini N, Brunasso AMG, Burlando M, Caldarola G, Campanati A, Carugno A, Castelli F, Conti A, Costanzo A, Cuccia A, Dapavo P, Dattola A, De Simone C, Di Lernia V, Dini V, Donini M, Errichetti E, Esposito M, Fargnoli MC, Foti A, Fiorella C, Gargiulo L, Gisondi P, Guarneri C, Legori A, Lembo S, Loconsole F, Malagoli P, Marzano AV, Mercuri SR, Megna M, Micali G, Mortato E, Musumeci ML, Narcisi A, Offidani AM, Orsini D, Paolino G, Pellacani G, Peris K, Potenza C, Prignano F, Quaglino P, Ribero S, Richetta AG, Romanelli M, Rossi A, Strippoli D, Trovato E, Venturini M, Bianchi L. Campione E, et al. Among authors: costanzo a. Pharmaceuticals (Basel). 2024 Oct 16;17(10):1378. doi: 10.3390/ph17101378. Pharmaceuticals (Basel). 2024. PMID: 39459016 Free PMC article.
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up).
Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Silverberg JI, et al. Among authors: costanzo a. Br J Dermatol. 2024 Oct 23:ljae404. doi: 10.1093/bjd/ljae404. Online ahead of print. Br J Dermatol. 2024. PMID: 39438067
837 results